Liglimet 850 mg

Liglimet 2.5/850 is a combination oral antidiabetic medication containing Linagliptin (2.5 mg) and Metformin Hydrochloride (850 mg). This dual-action formula is designed to help manage blood sugar levels in adults with Type 2 Diabetes Mellitus, complementing lifestyle interventions such as diet and exercise.

Key Features:

1. Dual Mechanism of Action:
   • Linagliptin: A DPP-4 inhibitor that increases incretin levels, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
   • Metformin Hydrochloride: A biguanide that reduces hepatic glucose production, improves insulin sensitivity, and decreases intestinal glucose absorption.
2. Comprehensive Glycemic Control: Targets both fasting and postprandial glucose levels for effective diabetes management.
3. Convenience: Combines two complementary agents in one tablet, simplifying treatment regimens and improving patient compliance.

Indications:
Liglimet 2.5/850 is indicated as an adjunct to diet and exercise for improving glycemic control in adults with Type 2 Diabetes Mellitus, especially in cases where single-agent therapy is insufficient.

Dosage and Administration:
Typically taken orally twice daily with meals to minimize gastrointestinal side effects. The dosage should be individualized based on the patient’s clinical response and tolerability under a healthcare provider’s guidance.

Safety Profile:
Liglimet 2.5/850 is generally well-tolerated. Common side effects include gastrointestinal discomfort, such as nausea or diarrhea. Rare but serious risks include lactic acidosis (associated with metformin) and hypersensitivity reactions.

Conclusion:
Liglimet 2.5/850 is an effective and convenient option for Type 2 Diabetes Mellitus management, combining the complementary benefits of Linagliptin and Metformin. Always use under medical supervision to achieve optimal glycemic control and minimize risks.